The purpose of this study is to determine whether lanreotide 30mg microparticles are effective in the relief of clinical symptoms due to small bowel obstruction in inoperable patients with peritoneal carcinomatosis.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
80
A single 30 mg intra-muscular injection on day 0. The duration of the blinded phase is 10 days. Patients may enter the open phase where they receive 30 mg intra-muscular injections, every 10 days until investigator/or patient decide to stop treatment.
A single intra-muscular injection on day 0.
Percentage of responder patients (patient with 1 or less vomiting episode per day during at least 3 consecutive days or in whom nasogastric tube (NGT) has been removed during at least three consecutive days without vomiting recurrence)
Time frame: On day 7 (plus 1 day at the latest) after the first injection
Number of daily vomiting episodes or measurement of the daily drainage by NGT
Time frame: Daily for the duration of the study
Number of days with no vomiting episodes
Time frame: For the duration of the study
Number of daily nausea episodes
Time frame: Daily for the duration of the study
Intensity of abdominal pain
Time frame: Daily for the duration of the study
Well-being
Time frame: Daily for the duration of the study
Symptom relief duration
Time frame: Between the first day of clinical response and the end of follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Clinique Universitaire St. LUC
Brussels, Belgium
Institut Jules Bordet
Brussels, Belgium
Clinique Notre-Dame
Hermalle-sous-Huy, Belgium
Centre Hospitalier de Jolimont-Lobbes
La Louvière, Belgium
Hôpital Nord
Amiens, France
Clinique de l'Anjou
Angers, France
Hôtel-Dieu
Angers, France
CH Victor Dupouy
Argenteuil, France
Hôpital Saint André
Bordeaux, France
Hôpital de la Cavale Blanche
Brest, France
...and 43 more locations